CORE LABORATORIES INC (CLB)

US21867A1051 - Common Stock

18.38  +0.25 (+1.38%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CLB. CLB was compared to 65 industry peers in the Energy Equipment & Services industry. CLB has an average financial health and profitability rating. While showing a medium growth rate, CLB is valued expensive at the moment.



5

1. Profitability

1.1 Basic Checks

CLB had positive earnings in the past year.
CLB had a positive operating cash flow in the past year.
Of the past 5 years CLB 4 years were profitable.
Each year in the past 5 years CLB had a positive operating cash flow.

1.2 Ratios

CLB's Return On Assets of 6.26% is fine compared to the rest of the industry. CLB outperforms 67.69% of its industry peers.
The Return On Equity of CLB (16.32%) is better than 80.00% of its industry peers.
CLB's Return On Invested Capital of 8.97% is fine compared to the rest of the industry. CLB outperforms 67.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CLB is in line with the industry average of 8.01%.
The 3 year average ROIC (7.69%) for CLB is below the current ROIC(8.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.26%
ROE 16.32%
ROIC 8.97%
ROA(3y)4.34%
ROA(5y)1.8%
ROE(3y)13.16%
ROE(5y)-7.94%
ROIC(3y)7.69%
ROIC(5y)8.82%

1.3 Margins

CLB's Profit Margin of 7.20% is fine compared to the rest of the industry. CLB outperforms 63.08% of its industry peers.
CLB's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 11.27%, CLB is doing good in the industry, outperforming 63.08% of the companies in the same industry.
CLB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 21.54%, CLB is doing worse than 61.54% of the companies in the same industry.
CLB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 11.27%
PM (TTM) 7.2%
GM 21.54%
OM growth 3Y-2.8%
OM growth 5Y-8.16%
PM growth 3YN/A
PM growth 5Y-8.71%
GM growth 3Y-2.28%
GM growth 5Y-5.83%

5

2. Health

2.1 Basic Checks

CLB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for CLB has been increased compared to 1 year ago.
Compared to 5 years ago, CLB has more shares outstanding
The debt/assets ratio for CLB has been reduced compared to a year ago.

2.2 Solvency

CLB has an Altman-Z score of 3.17. This indicates that CLB is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.17, CLB is doing good in the industry, outperforming 75.38% of the companies in the same industry.
The Debt to FCF ratio of CLB is 11.48, which is on the high side as it means it would take CLB, 11.48 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 11.48, CLB is in line with its industry, outperforming 43.08% of the companies in the same industry.
CLB has a Debt/Equity ratio of 0.73. This is a neutral value indicating CLB is somewhat dependend on debt financing.
CLB's Debt to Equity ratio of 0.73 is on the low side compared to the rest of the industry. CLB is outperformed by 67.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 11.48
Altman-Z 3.17
ROIC/WACC1.05
WACC8.52%

2.3 Liquidity

CLB has a Current Ratio of 2.53. This indicates that CLB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CLB (2.53) is better than 69.23% of its industry peers.
CLB has a Quick Ratio of 1.72. This is a normal value and indicates that CLB is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.72, CLB is doing good in the industry, outperforming 67.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.72

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.39% over the past year.
CLB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.70% yearly.
Looking at the last year, CLB shows a small growth in Revenue. The Revenue has grown by 4.10% in the last year.
CLB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.17% yearly.
EPS 1Y (TTM)17.39%
EPS 3Y0.84%
EPS 5Y-18.7%
EPS Q2Q%0%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y1.52%
Revenue growth 5Y-6.17%
Sales Q2Q%1%

3.2 Future

The Earnings Per Share is expected to grow by 13.26% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.60% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y42.07%
EPS Next 3Y25.76%
EPS Next 5Y13.26%
Revenue Next Year-1.43%
Revenue Next 2Y6.82%
Revenue Next 3Y3.69%
Revenue Next 5Y2.6%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

3

4. Valuation

4.1 Price/Earnings Ratio

CLB is valuated rather expensively with a Price/Earnings ratio of 22.69.
The rest of the industry has a similar Price/Earnings ratio as CLB.
When comparing the Price/Earnings ratio of CLB to the average of the S&P500 Index (27.82), we can say CLB is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 11.24, the valuation of CLB can be described as reasonable.
CLB's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of CLB to the average of the S&P500 Index (19.80), we can say CLB is valued slightly cheaper.
Industry RankSector Rank
PE 22.69
Fwd PE 11.24

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CLB is valued a bit more expensive than 78.46% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CLB is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 60.66
EV/EBITDA 13.63

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as CLB's earnings are expected to grow with 25.76% in the coming years.
PEG (NY)1.7
PEG (5Y)N/A
EPS Next 2Y42.07%
EPS Next 3Y25.76%

3

5. Dividend

5.1 Amount

CLB has a yearly dividend return of 0.22%, which is pretty low.
CLB's Dividend Yield is comparable with the industry average which is at 3.09.
With a Dividend Yield of 0.22, CLB pays less dividend than the S&P500 average, which is at 2.37.
Industry RankSector Rank
Dividend Yield 0.22%

5.2 History

The dividend of CLB decreases each year by -73.70%.
CLB has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of CLB decreased in the last 3 years.
Dividend Growth(5Y)-73.7%
Div Incr Years0
Div Non Decr Years2

5.3 Sustainability

CLB pays out 5.09% of its income as dividend. This is a sustainable payout ratio.
DP5.09%
EPS Next 2Y42.07%
EPS Next 3Y25.76%

CORE LABORATORIES INC

NYSE:CLB (5/30/2024, 11:05:15 AM)

18.38

+0.25 (+1.38%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap862.02M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 0.22%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 22.69
Fwd PE 11.24
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.7
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.26%
ROE 16.32%
ROCE
ROIC
ROICexc
ROICexgc
OM 11.27%
PM (TTM) 7.2%
GM 21.54%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.53
Quick Ratio 1.72
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.39%
EPS 3Y0.84%
EPS 5Y
EPS Q2Q%
EPS Next Y13.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.1%
Revenue growth 3Y1.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y